The cholecystokinin effect on human intestinal permeability: influence of chenodeoxycholic and ursodeoxycholic acid administration.
The influence of CDCA and UDCA administration on human intestinal permeability to lactulose, as disclosed by intravenous CCK, has been investigated. For this purpose the fraction of lactulose excreted in the urine during 5 h after an oral load of the disaccharide in hypertonic solution was measured in 12 healthy subjects, with and without intravenous CCK. The lactulose test was performed in each subject before and after a 7-day course of oral CDCA or UDCA (750 mg/day). Under basal conditions CCK induced a 100% increase in lactulose excretion. CDCA treatment further augmented the response to CCK by 33% (p less than 0.001) but UDCA produced no significant change. Finally, the effect of CDCA or UDCA added directly to the lactulose test solution was investigated in 4 subjects following oral and duodenal administration. CDCA only produced an increase in lactulose excretion (more than 100%) when given in hypertonic solution. The possible reasons for these findings are discussed.
D000284:Administration, Oral; D000328:Adult; D002635:Chenodeoxycholic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D002766:Cholecystokinin / Q000494:pharmacology*; D003840:Deoxycholic Acid / Q000031:analogs & derivatives*; D004187:Disaccharides / Q000378:metabolism*; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism*; D007792:Lactulose / Q000378:metabolism* / Q000652:urine; D008297:Male; D008875:Middle Aged; D010539:Permeability; D014580:Ursodeoxycholic Acid / Q000008:administration & dosage / Q000494:pharmacology*
D004187:Disaccharides; D003840:Deoxycholic Acid; D002635:Chenodeoxycholic Acid; D007792:Lactulose; D014580:Ursodeoxycholic Acid; D002766:Cholecystokinin